summary of Research: SGLT2 Inhibitors vs. GLP-1RAs for Kidney Protection in Type 2 diabetes
Key Finding: Recent research suggests that SGLT2 inhibitors are associated with better renal outcomes (chronic and acute kidney disease) compared to GLP-1 receptor agonists in individuals with type 2 diabetes.
Study Details:
* Design: Large, population-based comparative effectiveness study using Danish national health register data.
* Participants: 36,279 individuals initiating SGLT2 inhibitors and 18,782 initiating GLP-1RAs, all treated with metformin.
* Follow-up: January 2014 – October 2024 (up to 5 years).
* Outcomes:
* Co-primary: chronic Kidney Disease (CKD – defined as a 40% decline in eGFR,severe albuminuria,or kidney failure) and Acute Kidney Injury (AKI).
* Secondary: new or worsening albuminuria, and mortality.
Results:
* CKD: 5-year risk was 6.7% with SGLT2 inhibitors vs. 8.2% with GLP-1RAs (risk ratio 0.81, absolute risk reduction 1.5%). The benefit was driven by lower risks of eGFR decline and kidney failure.
* AKI: Lower risk with SGLT2 inhibitors (25.2 events per 100 individuals) compared to GLP-1RAs (28.7 events per 100 individuals).
* Mortality: Slightly lower with GLP-1RAs (9.3%) vs. SGLT2 inhibitors (9.7%), but not statistically notable.
* Albuminuria: GLP-1RAs showed slightly lower risks of new or worsening albuminuria.
* Subgroup Analysis: Renal benefits of SGLT2 inhibitors were greatest in those without pre-existing kidney disease.
Conclusion:
The study supports the preferential use of SGLT2 inhibitors for renal protection in people with type 2 diabetes, especially for primary prevention. Further research is needed to explore the benefits of combination therapy.
Limitations:
* Lack of BMI data.
* Potential for residual confounding.
* limited generalizability beyond Nordic populations.